Skip to main content

Toronto’s financial district at the corner of Bay and Adelaide streets.

Gloria Nieto/The Globe and Mail

Callidus Capital Corp. has filed a lawsuit against a group of investors and borrowers in Canada and the United States for allegedly working in concert to drive down the price of the distressed-debt lender's shares.

The Toronto-based company filed the lawsuit on Tuesday in an Ontario court. It is suing a group of investment firms – which it calls the "wolfpack conspirators" – that includes private-equity firm West Face Capital Inc., hedge fund Anson Group and several companies related to it, and ClaritySpring Inc.

The lawsuit alleges that the "conspirators" took short positions in Callidus and engaged in a "wave of short attacks against Callidus" in a bid to profit as shares fell, according to court filings. Callidus is also claiming that these people "spread false information through the Bay Street rumour mill" and then worked with members of the press to publish a "negative and false" story about Callidus.

Story continues below advertisement

"The conspiracy required very sophisticated co-ordination and perfect timing under the hand of the wolfpack conspirators," says the claim filed by Callidus.

None of the allegations have been proven in court.

Callidus is seeking either $450-million in damages or, alternatively, the amount the investors allegedly earned by trading Callidus shares or betting against the stock since Aug. 9. The lawsuit also calls for the investors to admit they defamed Callidus.

This is the fourth legal action Catalyst Capital Group Inc., the private-equity parent of Callidus, has launched against West Face and its principal, Gregory Boland. West Face said in a statement that it has "prevailed" over Catalyst in the two previous matters that have proceeded to hearings or trial.

"Catalyst's allegations are completely devoid of merit, and will be defended vigorously at every turn," West Face added in its statement.

West Face said it hasn't shorted the shares of Callidus in more than two years and has not spoken to Anson about any investment Anson has made in Callidus.

Anson and ClaritySpring didn't immediately respond to a request for comment.

Story continues below advertisement

In its statement of claim, Callidus alleges that the defendants entered into an agreement to work together to harm Callidus. Months after the alleged agreement took place, the Wall Street Journal published an article on Aug. 9 by reporter Rob Copeland, who is named in the lawsuit, that stated Callidus is the subject of whistle-blower complaints with Canada's largest market regulator.

The article reported that at least four complaints have been filed with the Ontario Securities Commission claiming fraud at the firm and Catalyst. The Journal article also said a unit of the Toronto Police Service that specializes in financial crimes had started its own inquiries.

Shares of Callidus tumbled after the article was published.

Callidus said it had not been contacted by authorities about these complaints, adding that the company has adhered to "the highest ethical standards" in its business practices.

Mr. Copeland declined to comment.

A spokesman for Dow Jones, which is owned by News Corp. and publishes The Wall Street Journal, said in an e-mail: "We are confident in the fairness and accuracy of our reporting. We firmly stand behind Rob."

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies